The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AmSurg's revenues will grow 13.6% and EPS will grow 4.0%.
The average estimate for revenue is $261.4 million. On the bottom line, the average EPS estimate is $0.52.
Last quarter, AmSurg recorded revenue of $244.2 million. GAAP reported sales were 10% higher than the prior-year quarter's $217.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.49. GAAP EPS of $0.53 for Q4 were 26% higher than the prior-year quarter's $0.42 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 53.9%, 90 basis points worse than the prior-year quarter. Operating margin was 29.8%, 10 basis points better than the prior-year quarter. Net margin was 7.0%, 80 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.07 billion. The average EPS estimate is $2.18.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 140 members out of 148 rating the stock outperform, and eight members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give AmSurg a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmSurg is hold, with an average price target of $28.64.
Is AmSurg the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add AmSurg to My Watchlist.